• Oversonic Robotics

  Led · Equity · Jun 2026

  Oversonic Robotics is a 2020-founded Italian deep tech firm focused on cognitive computing and humanoid robotics, headquartered in Carate Brianza with a team of 65 professionals. Its flagship platform, RoBee, is described as the first certified cognitive humanoid robot designed to operate in complex industrial environments and in healthcare settings. RoBee is already operating in manufacturing applications and is being developed for potential healthcare uses including assistance, logistics and operator support. The company positions RoBee as a platform to interact with people, machinery and environments via artificial intelligence. With the new capital and industrial partners, Oversonic plans to accelerate technological development, industrialization and international expansion, targeting broader deployments in Europe and the United States. The articles do not disclose revenue or user metrics.

• WISE

  Participated · Series D · Jun 2026

  WISE develops implantable, stretchable electronic electrodes using its proprietary Supersonic Technology to create ultra-thin elastomeric foils that aim to improve tissue conformability, softness, adhesion and signal sensing versus rigid electrodes. Its lead product in the round, the Heron lead, is a spinal cord stimulation device designed to deliver targeted directional stimulation via a minimally invasive percutaneous implant technique and to combine the precision of paddle leads with the procedural ease of cylindrical leads. WISE also markets the WISE Cortical Strip, a soft and stretchable electrode for intraoperative neurophysiological monitoring that has CE marking under MDR, FDA clearance, and is commercially available in Europe, the U.S., and Australia. The company plans to use the Series D proceeds to complete the Heron lead’s regulatory certification pathway, fund a first-in-human study, and scale commercialization of its electrode portfolio across target markets. The company positions its technology to support higher energy efficiency, improved anatomical coverage, better neural signal sensing, and reduced lead migration. The financing coincided with governance updates, including the appointment of Laura Iris Ferro as Chairperson and the addition of Giuseppe Corvino to the board.

• CellPly

  Led · Equity · May 2026

  Cellply develops analytical tools for cell therapy and regenerative medicine, with its flagship VivaCyte platform at the center of its commercial strategy. VivaCyte combines patented microfluidic technology, AI-powered automated image analysis, comprehensive automation, and dedicated software to enable characterization of immunotherapies and cell-based therapies at single-cell resolution. The company is prioritizing international expansion of VivaCyte and the development of automated functional testing solutions to improve cell potency assessment and streamline batch release for ATMPs. Cellply framed these quality-control solutions as critical to enabling scalability, sustainability, and broader patient access to complex and personalized medicines. The company has strengthened its board with the addition of Miro Venturi as it scales commercially. Cellply aims to become a global leader in analytical tools for research and quality control in the cell therapy and regenerative medicine sectors.

• Recornea

  Led · Seed · Aug 2025

  Recornea is a clinical-stage Italian medtech company developing the GROSSO® Reshaper, a nitinol corneal implant designed to restore vision in patients with keratoconus. The GROSSO® Reshaper uses a predefined physiological curvature to remodel the cornea with predictable visual results and is built on a nitinol platform that the company says can be applied to other ocular conditions. Recornea completed preclinical work including biocompatibility testing and a six-month rabbit study showing the implant was well tolerated. A First-in-Human (FIH) study on 12 patients is underway at the Instituto de Microcirugía Ocular (IMO) in Barcelona, with a second FIH planned at Fondazione Policlinico Universitario Agostino Gemelli IRCCS in Rome; the first implanted patient showed excellent safety and promising early efficacy. The company is also exploring a nitinol-based filtering device for glaucoma as a second product in its pipeline. Funds recently raised will be used to complete the ongoing FIH studies and advance the pipeline toward larger clinical trials and commercialization. Recornea has developed GROSSO, the first nitinol corneal implant designed to help patients with advanced keratoconus recover vision. The implant can be inserted via a conservative-additive refractive surgery that does not require removal of corneal tissue. Recornea says its technology restores the physiological curvature of the cornea, a significant improvement over traditional intracorneal ring segments. Current standards cited in the article include corneal cross-linking for early disease and ICRS for advanced cases. The company aims to improve quality of life for keratoconus patients and integrate its solution into routine clinical practice. Recornea announced a €150,000 financing led by Scientifica Venture Capital to support these efforts.

• Valo Therapeutics

  Participated · Equity · Mar 2025

  Valo Therapeutics develops tumor antigen-coated replication-competent oncolytic viruses as therapeutic vaccines (its lead platform is PeptiCRAd) and a microchip-based neoantigen identification tool (PeptiCHIP). The company is led by David Hinton and is focused on advancing its lead tumour antigen-coated oncolytic virus candidate through clinical development. It received €19M in funding to expand and complete a Phase 1B clinical study of that lead candidate. The financing will also fund creation of an Italian operating company, Valo Therapeutics Italy Srl, based in Naples to enroll and treat patients in Southern Italy. Part of the investment will support initiation of large-scale manufacturing of the virus-supporting product to advance development toward the commercial phase. Funds will additionally support research activities at institutions in Naples and southern Italy. Valo Therapeutics is a Helsinki-based developer of adaptable immunotherapies for cancer and infectious diseases. Led by CEO Paul Higham, the company focuses on antigen-coated oncolytic viruses and vaccine vectors as therapeutic vaccines. Its lead platform, PeptiCRAd (Peptide-coated Conditionally Replicating Adenovirus), was developed out of Professor Vincenzo Cerullo’s laboratory at the University of Helsinki and aims to activate systemic anti-tumor cytotoxic T-cell immunity without the need to generate multiple genetically modified viruses. Valo is developing several neoantigen strategies including PeptiCHIP, a novel microchip-based technology that rapidly identifies a tumor’s antigen presentation profile to drive personalized immunotherapies, as well as PeptiENV and PeptiVAX. The company intends to use the €2.23M EIC grant to progress a project named "Pre-clinical validation and demonstration of PeptiCHIP." The EIC award is a 100% non-dilutive grant and also provides Business Acceleration Services including coaching, mentoring, and partnering events. Valo Therapeutics develops antigen-coated oncolytic adenoviruses and adaptable vaccine vectors — its lead platform is PeptiCRAd (Peptide-coated Conditionally Replicating Adenovirus) derived from the University of Helsinki. The company is advancing its lead candidate, PeptiCRAd-1, and also develops anti-infectives platforms including PeptiBAC, PeptiVAX and PeptiENV. Proceeds from the recent financing will be used to finalise preparations and initiate a Phase 1 clinical study of PeptiCRAd-1 and to continue development of the anti-infectives programs. Valo plans to use part of the funds to support preparation for an IPO in 2022. The company reported it raised €11M in the most recent Pre-IPO funding, bringing total funding to date to over €22M. Valo is led by CEO Paul Higham and recently promoted co-founder Dr. Sari Pesonen to Chief Scientific Officer. Valo Therapeutics develops peptide‑coated conditionally replicating adenoviruses (PeptiCRAd) to turn oncolytic adenoviruses into targeted cancer vaccines without creating multiple genetically modified viruses. The company also develops PeptiENV and other neoantigen strategies in collaboration with Professor Vincenzo Cerullo to improve responses to enveloped oncolytic viruses. Its PeptiCRAd platform was developed out of Professor Cerullo’s laboratory at the University of Helsinki. Led by CEO Dr Michael Stein, Valo plans to progress PeptiCRAd into first‑in‑human clinical trials, with the initial clinical program targeting melanoma, lung cancer and triple negative breast cancer. The company has operations linked to Oxford, UK and Helsinki, Finland. Financially, the company has raised a total of over EUR 10m to date, including recent additional funding.

No current team members are available.